SSA
RANI icon

Schonfeld Strategic Advisors’s Rani Therapeutics RANI Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4K Buy
+14,200
New +$18.1K ﹤0.01% 2091

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Schonfeld Strategic Advisors's RANI Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Rani Therapeutics (RANI) in Q1 2026: 14,200 shares worth $10.4K. The stake represents ﹤0.01% of the portfolio and ranks #2091 among its holdings.

74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Schonfeld Strategic Advisors held 14,200 shares of Rani Therapeutics worth $10.4K as of Q1 2026.
  • Rani Therapeutics was a new Schonfeld Strategic Advisors position in Q1 2026.
  • Rani Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #2091 holding.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.